Compare Amkor Technology (AMKR) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amkor Technology vs Charles River Laboratories Intl. Inc — how do they compare? Amkor Technology trades at $47.5 (market cap $11.52B), while Charles River Laboratories Intl. Inc trades at $272.89 (market cap $13.03B). The key difference: Amkor Technology and Charles River Laboratories Intl. Inc are close in size by market cap, and Amkor Technology pays a 0.72% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amkor Technology for 2 Days and Charles River Laboratories Intl. Inc for 34 Days on average.
| AMKR | CRL | |
|---|---|---|
Market Cap | $11.52B | $13.03B |
Volume | 5,086,153 | 975,636 |
Sector | Technology | Health |
52-Week High | $93.55 | $298.58 |
52-Week Low | $26.62 | $145.57 |
Typical Hold Time | 2 Days | 34 Days |
Enterprise Value | $11.60B | $15.86B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amkor Technology (AMKR) trades at $46.38, down 10.34% amid bearish technical signals, though fundamentals show strength with three consecutive quarterly earnings beats and a 7.45% net income margin. The company's $12 billion Arizona expansion and partnerships with TSMC and NVIDIA highlight growth potential in advanced semiconductor packaging.
The stock offers significant upside based on a $77 consensus price target, but near-term volatility and competitive pressures pose risks. Long-term investors may find value given solid cash flow and analyst optimism, though technical weakness warrants caution.
Charles River Laboratories (CRL) trades at $272.53, down 2.06% today but near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and oversold RSI signals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 contrast with negative net income margins, while revenue holds steady at $4.02 billion. Positive cash flow trends and strategic collaborations, like the Medigen vaccine partnership announced August 20, 2026, support growth prospects.
Outlook remains cautiously optimistic with a consensus price target of $280.14, though high P/E of 684.85 and net losses pose valuation risks. Key opportunities include sustained earnings outperformance and DSA demand growth; risks involve NHP cost volatility and margin pressure. Analyst sentiment is strongly bullish with 72% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Amkor Technology
Amkor Technology provides outsourced semiconductor packaging and test services. It helps chipmakers assemble, protect, and test semiconductors for computing, communications, automotive, and consumer applications.
Read more on AMKR →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
